GelSana is proud to announce that we have been awarded another NIH SBIR Phase I funding through the NIDDK for the development of a polymer designed for the sustained delivery of a therapeutic growth factor to treat diabetic foot ulcers. This is another significant milestone propelling us forward in our mission to redefine the future of wound care and to change how wounds are healed.
At GelSana, we understand the critical role that inflammation and regenerative factors play in the wound healing process. This NIDDK SBIR Phase I project focuses on delivering a therapeutic growth factor in a controlled manner over time from our proprietary polymers to improve healing of diabetic wounds. This approach has the potential to revolutionize how these difficult chronic wounds heal and provide patients with a safe, effective, easy to apply therapeutic topical product.
GelSana is honored to collaborate with the National Institutes of Health through the SBIR program. This partnership underscores the potential impact of our polymer technology on advancing wound care practices and aligns with our commitment to innovation in the healthcare landscape. The successful completion of this NIH SBIR Phase I project will be a significant step forward, setting the stage for subsequent phases of funding. GelSana is eager to continue refining and validating our hydrogel technology, working towards the ultimate goal of translating this innovation into real-world applications that benefit both patients and healthcare providers.